Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 1167 for:    MYCOPHENOLIC ACID

A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS) (AUC-MPA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01822483
Recruitment Status : Completed
First Posted : April 2, 2013
Last Update Posted : April 3, 2015
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Valter Duro Garcia, Irmandade Santa Casa de Misericórdia de Porto Alegre

Brief Summary:
The purpose of this study is investigate mycophenolic acid exposure through area under the curve in renal transplants recipients treated with mycophenolate mofetil and after conversion to mycophenolate sodium.

Condition or disease Intervention/treatment Phase
Renal Transplantation Drug: Mycophenolate sodium Drug: Mycophenolate mofetil Phase 4

Detailed Description:

A growing body of evidence has shown that mycophenolate acid (MPA) exposure assessment and dosage adjustment are necessary in patients treated with mycophenolate mofetil (MMF), but there is still limited information about the dose-exposure-effect relationship of the enteric-coated mycophenolate sodium (EC-MPS) formulation that has quite different physicochemical properties (TETT et al., 2011).

Pharmacokinetically guided exposure-controlled area under the concentration-time curve (AUC) approaches are helpful to limit interpatient variability of MPA exposure and to improve the clinical outcome of organ transplant recipients (TETT et al., 2011).

MPA area under the concentration-time curve values between 30 and 60 μg h/mL in the early post-transplant period reduces the risk of acute rejections and seems to be appropriate in renal allograft recipients taking mycophenolate sodium (MPS) and calcineurin inhibitors (GRINYÓ et al., 2009; SOMMERER et al., 2010).

Among the benefits of therapeutic drug monitoring of MPA are the evaluation of interaction between MPA and proton pump inhibitors and association of donor-specific antibodies reduction.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)
Study Start Date : April 2013
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015


Arm Intervention/treatment
Experimental: Mycophenolate sodium
Arm1(Conversion):MPA AUC below 30mcg*h ml-1 - MPS+Calcineurin inhibitor+prednisone
Drug: Mycophenolate sodium
The conversion will be performed abruptly for all patients. Mycophenolate mofetil will be discontinued one day before the day of conversion (Day 1). Mycophenolate sodium will be introduced on day 1 with equivalent doses.

Active Comparator: Mycophenolate mofetil
Arm2(Maintained):MPA AUC between 30 to 60 mg*h ml-1 or above 60 mg - MMF+Calcineurin inhibitor+prednisone
Drug: Mycophenolate mofetil
Mycophenolate mofetil dose will be maintained or adjusted to keep 30 to 60 mg*h ml-1.




Primary Outcome Measures :
  1. Evaluate the frequency of renal transplants recipients taking mycophenolate mofetil (MMF) with MPA AUC below target level (30mcg*h ml-1). [ Time Frame: Baseline ]
    Evaluate the frequency of renal transplants recipients taking mycophenolate mofetil (MMF) with MPA AUC below target level (30mcg*h ml-1).


Secondary Outcome Measures :
  1. Evaluate the association of MPA AUC in renal transplant recipients with donor specific antibodies (DSA); [ Time Frame: Baseline; month 6. ]
    Evaluate the association of MPA AUC in renal transplant recipients with donor specific antibodies (DSA);

  2. Evaluate the interaction between MMF or EC-MPS and the proton pump inhibitor omeprazole through the AUC in patients with MPA below target level (30mcg*h ml-1). [ Time Frame: 6 months ]
    Evaluate the interaction between MMF or EC-MPS and the proton pump inhibitor omeprazole through the AUC in patients with MPA below target level (30mcg*h ml-1).

  3. Evaluate the association of MPA AUC with renal function estimated by MDRD formula. [ Time Frame: Baseline; day one; months 2, 4 and 6. ]
    Evaluate the association of MPA AUC with renal function estimated by MDRD formula.

  4. Evaluate the MPA_AUC in renal transplant patients converted to mycophenolate sodium (MPS) with equivalent dose of mycophenolate mofetil (MMF). [ Time Frame: Baseline, five days after day one, fourteen days after day one, months 2,4 and 6 ]
    Evaluate the MPA_AUC in renal transplant patients who were taking mycophenolate mofetil (MMF) and were converted to the use of mycophenolate sodium (MPS) by having the MPA concentration below the target level of 30 mcg*h ml-1.

  5. Evaluate the MPA_AUC in renal transplant patients maintained with mycophenolate mofetil (MMF). [ Time Frame: baseline, months 2,4 and 6 ]
    Evaluate the AUC_MPA in renal transplant patients maintained with mycophenolate mofetil(MMF) by having the MPA concentration between 30-60 mcg*h ml-1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years at the time of screening;
  • Subjects above the sixth month post renal transplant;
  • Subjects receiving mycophenolate mofetil;
  • Women of childbearing potential (CBP) with a negative pregnancy test at screening (urine or serum);
  • Women of CBP and men with sexual partners of CBP must agree to use a medically acceptable method of contraception throughout the study.

Exclusion Criteria:

  • Subjects who, in the opinion of the investigator, are not able to complete the study;
  • Recipients of multiple organ transplant (i.e., prior or concurrent transplantation of a non-renal allograft;
  • Use of any investigational drug or treatment up to 4 weeks before enrollment;
  • Subjects with a calculated GFR < 30ml/min (abbreviated MDRD formula);
  • Subjects with a screening total white blood cell count (WBC) ≤ 2000/mm3, hemoglobin ≤ 10g/dL and platelet count ≤ 100000/mm3;
  • TGO/AST, TGP/ALT and bilirubin with values three times higher that reference values;
  • History of malignancy within 3 years enrollment other than adequately treated basal cell or squamous cell carcinoma of the skin;
  • Subjects who are known to be human immunodeficiency virus (HIV), hepatitis B or hepatitis C;
  • Chronic hepatic failure;
  • Planned treatment with immunosuppressive therapies other than those described in the protocol;
  • Recipients who required desensitization protocols.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01822483


Locations
Layout table for location information
Brazil
Irmandade Da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90020090
Sponsors and Collaborators
Irmandade Santa Casa de Misericórdia de Porto Alegre
Novartis
Investigators
Layout table for investigator information
Principal Investigator: Valter Garcia, Physician IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE
Study Chair: Elizete Keitel, Physician IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE
Study Chair: Daniela Seelig, Physician IRMANDADE DA SANTA CASA DE MISERICÓRIDA DE PORTO ALEGRE
Study Chair: Fabiano Klaus, Physician IRMANDADE DA SANTA CASA DE MISERICÓRIDA DE PORTO ALEGRE
Study Director: Ronivan Dal Pra, Pharmacist IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE
Study Director: Larissa Pacheco, Pharmacist IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE
Study Director: Bruna Cardoso, Pharmacist IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE
Study Director: Roger Kist, Trainee IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE
Study Director: Helen Zanetti, Pharmacist IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE

Publications:
Layout table for additonal information
Responsible Party: Valter Duro Garcia, PHYSICIAN NEPHROLOGY, Irmandade Santa Casa de Misericórdia de Porto Alegre
ClinicalTrials.gov Identifier: NCT01822483     History of Changes
Other Study ID Numbers: CERL080
CERL080ABR08T ( Other Identifier: NOVARTIS )
First Posted: April 2, 2013    Key Record Dates
Last Update Posted: April 3, 2015
Last Verified: April 2015

Keywords provided by Valter Duro Garcia, Irmandade Santa Casa de Misericórdia de Porto Alegre:
Renal transplantation
mycophenolic acid
mycophenolate mofetil
mycophenolate sodium
area under the curve

Additional relevant MeSH terms:
Layout table for MeSH terms
Mycophenolic Acid
Calcineurin Inhibitors
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action